Is Wegovy Available in Ireland? (2026)

All medical information is reviewed by our clinical partners at MedicOnline.

Dr. Jahan Khan, CMO @ MedicOnline

IMC 409788

Ready to start? Skip to the answer.

Yes - Wegovy is available in Ireland. But if you are searching for it, you probably want to know more than that: what it actually costs, how reliable the supply is, how to make sure what you are getting is genuine, and what a higher dose now available in the EU means for you. This guide covers all of it.

Wegovy became formally available in Irish pharmacies on 24 March 2025 - making Ireland one of more than 15 countries worldwide where patients can now access the medication. It is available on private prescription only. No GP referral is required if you go through a specialist weight management service.

What Is Wegovy - and How Is It Different From Ozempic?

This is Ireland's most searched question about semaglutide - and it is a genuinely important one, because using the wrong product can put you at clinical risk.

Wegovy is the brand name for semaglutide at a 2.4 mg weekly maintenance dose, manufactured by Novo Nordisk and specifically licensed for weight management in adults. It is not the same as Ozempic, despite containing the same active ingredient. Ozempic is semaglutide at a lower dose (maximum 2 mg) licensed exclusively for type 2 diabetes management. Wegovy's EU marketing authorisation is specifically for weight management - the dosing, the clinical trials behind it, and the regulatory indication are all distinct.

Why does this matter? Since Wegovy, Saxenda, and Mounjaro became formally approved for weight management in Ireland, regulatory scrutiny on off-label prescribing has tightened. Prescribing Ozempic for weight loss when licensed alternatives now exist is outside good clinical practice - and patients who source Ozempic for weight management via informal routes are taking an unnecessary legal and clinical risk.

How Wegovy Works

Wegovy is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a gut hormone naturally released after eating, which signals fullness to the brain, slows gastric emptying, and reduces appetite. Semaglutide binds to GLP-1 receptors with approximately 94% structural similarity to the natural hormone - making it a highly effective appetite suppressant.

In the STEP 1 trial (Wilding et al., NEJM, 2021) (full publication) - the landmark Phase 3 study of semaglutide 2.4 mg - participants lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group. Approximately one in three participants lost 20% or more.

Supply in Ireland: The History and Where Things Stand Now

Understanding supply matters because Wegovy's journey to Irish pharmacies was not straightforward - and intermittent availability issues have not entirely disappeared.

Wegovy received its EU marketing authorisation for weight management in January 2022, but it did not reach Irish pharmacies for more than three years after that. The reason was manufacturing capacity. Novo Nordisk - which also makes Ozempic - faced unprecedented global demand for semaglutide products simultaneously across diabetes and obesity indications. The company was forced to delay launches in market after market while expanding production. Ireland only received formal Wegovy availability in March 2025, long after the UK, the US, and much of northern Europe.

Since then, supply has stabilised significantly. Novo Nordisk has committed substantial investment to its Irish manufacturing facilities - its Chartham and Monge facilities in Limerick have been expanded, and fill-and-finish capacity at its Athlone plant has increased. The higher 7.2 mg dose (approved EU-wide February 2026) is being specifically manufactured for non-US markets at Novo Nordisk's Athlone facility.

The Counterfeit Crisis: A Real and Worsening Risk in Ireland

Ireland's illegal GLP-1 market has grown at a pace that has alarmed regulators, pharmacists, and clinicians. This is not a peripheral issue - it is directly relevant to anyone searching for Wegovy in Ireland in 2026.

The figures from the Health Products Regulatory Authority (HPRA) show that illegal GLP-1 products detained surged from 1,582 individual packages in 2024 to 48,752 in 2025 - a 30-fold increase in a single year. More than 750,000 units of illicit medicines were seized in total during 2025. Individual consignments linked to personal purchases rose 180% year on year.

The products seized were predominantly marketed as GLP-1 drops and transdermal microneedle patches - both formats for which no authorised Wegovy or semaglutide product exists. HPRA laboratory testing confirmed that the patches often contained no semaglutide at all. Patients were paying significant sums for products with zero active ingredient.

Beyond inert fakes, the HPRA has also warned about counterfeit injectable products. In late 2025, counterfeit pens were seized containing insulin instead of the labelled GLP-1 medication - a potentially fatal substitution for someone without diabetes, capable of causing severe hypoglycaemia, seizures, loss of consciousness, and death.

How to make sure your Wegovy is genuine

• ✓Only accept Wegovy dispensed by a PSI-registered pharmacy or equivalent regulated pharmacy with a valid prescription from an IMC-registered doctor.
• ✓Wegovy comes only as a pre-filled FlexTouch injection pen - there is no authorised liquid, drop, patch, powder, or tablet form.
• ✓Check the pen was refrigerated at the pharmacy - cold chain integrity is mandatory for a legitimate dispensing pharmacy.
• ✓Verify the expiry date and that the solution is clear and colourless to slightly yellow - not cloudy, discoloured, or containing particles.
• ✓Never purchase from social media, Instagram, TikTok, beauty salons, or websites offering next-day delivery without a prescription.
• ✓If anything about your pen seems wrong, do not inject it - contact the HPRA at hpra.ie or your pharmacist immediately.

The cold chain - why it matters specifically for Wegovy

Wegovy must be stored between 2°C and 8°C until removed from the fridge, after which it can be kept at room temperature below 30°C for up to 28 days. Any break in cold chain during storage or shipping can degrade the semaglutide without any visible change to the pen - producing a product that looks normal but delivers little or no therapeutic effect. PSI-registered pharmacies are legally required to maintain cold chain integrity. Unregulated sellers are not, and there is no way to verify their storage conditions from a website.

The Wegovy Dose Schedule

Wegovy is initiated at a low dose and escalated gradually over 16 weeks, giving your body time to adjust and minimising gastrointestinal side effects.

The 0.25 mg starting dose is a tolerability dose, not a treatment dose - its purpose is to prepare your body for the medication, not to produce weight loss. Many patients feel frustrated at this stage; this is normal and expected. Weight loss typically becomes more noticeable from month two onwards as the dose escalates.

The Wegovy 7.2 mg Dose: What It Means for Irish Patients

On 17 February 2026, the European Commission formally approved a new 7.2 mg weekly maintenance dose of Wegovy across all 27 EU member states. This is significant because it substantially closes the efficacy gap with Mounjaro (tirzepatide).

The STEP UP trial (Wharton et al., Lancet Diabetes Endocrinol., 2025) (full publication) showed that semaglutide 7.2 mg produced approximately 20.7% mean weight loss at 72 weeks with full adherence - compared to 17.5% at the standard 2.4 mg dose. Approximately 33% of participants on 7.2 mg achieved 25% or greater weight loss.

The 7.2 mg dose is a step-up option for patients who have reached and tolerated 2.4 mg but have not achieved their clinical goals. It is not a starting dose. Currently it is administered as three consecutive 2.4 mg injections weekly - a dedicated single-pen format is pending EU approval. Practical availability in Irish pharmacies is expected in the coming months of 2026. For a full breakdown, read our dedicated article: Wegovy 7.2 mg: what the EU approval means for patients in Ireland.

What Does Wegovy Cost in Ireland in 2026?

Wegovy is private prescription only in Ireland. It is not covered by the HSE, Medical Card, or Drugs Payment Scheme for weight management. You pay the full cost out of pocket - though both the medication and consultation qualify for 20% tax relief under Revenue's health expenses scheme, so keep all receipts. See our guide to claiming tax relief on weight management expenses for how this works.

Pricing varies by dose and by pharmacy. Here is an honest picture of current Irish market pricing for the medication alone:

These figures are medication cost estimates only and exclude consultation fees, which vary significantly between providers. Prices also vary between pharmacies - sometimes by €30-50 at the same dose level - which is why provider pharmacy network access matters. It's always best to check prices with your local pharmacy to confirm.

Who Is Eligible for Wegovy in Ireland?

Eligibility follows the criteria set out in the EMA Summary of Product Characteristics for Wegovy. You need either:

• A BMI of 30 kg/m² or above, or
• A BMI of 27-29.9 kg/m² alongside at least one weight-related health condition - such as high blood pressure, type 2 diabetes or prediabetes, high cholesterol, obstructive sleep apnoea, or cardiovascular disease.

Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It should not be used during pregnancy - due to semaglutide's approximate one-week half-life, stopping at least two months before planned conception is recommended. A full clinical assessment by an IMC-registered doctor is required before treatment begins.

For more detail, see Who qualifies for Wegovy in Ireland? and Is Wegovy safe? Side effects and risks.

Accessing Wegovy Through the Bua Health Weight Loss Programme

Most Wegovy prescription services in Ireland offer an assessment, a prescription, and a pharmacy link. Bua Health is built differently - because the evidence consistently shows that medication alone is not enough, and that patients supported throughout their treatment do significantly better than those left to manage alone.

The 2-minute online assessment is reviewed by an IMC-registered doctor through our clinical partners at MedicOnline the same working day. Most patients have their prescription approved and sent to a PSI-registered pharmacy within 24-48 hours - with cold chain-compliant dispensing through our verified pharmacy network. No GP referral needed.

Looking to get started with Wegovy?

The process through Bua Health is simple, secure, and strictly doctor-led:

Includes free dietitian support and full access to the Bua Health patient portal from day one.

Check your eligibility at buahealth.ie.

Sources and References

• 1. European Medicines Agency. Wegovy (semaglutide) Summary of Product Characteristics. EMA Wegovy EPAR
• 2. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. STEP 1 study publication
• 3. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. SELECT study publication
• 4. Luda Partners. GLP-1 medications in Ireland: illegal market figures from HPRA (pharmacist guide, 2026). ludapartners.ie guide
• 5. HPRA (October 2025). Health warning - counterfeit tirzepatide pens containing insulin (also relevant for illegal GLP-1 injectables). HPRA counterfeit injectable warning
• 6. Wharton S, et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP). Lancet Diabetes Endocrinol. 2025;13(11):949-963. STEP UP study publication
• 7. Irish Medical Times (March 2025). Weight loss drug Wegovy now available in Ireland. imt.ie article
• 8. Pharmaceutical Society of Ireland. Register of pharmacies. PSI pharmacy register

Related Blogs

Who Qualifies for Mounjaro in Ireland?

An overview of the clinical criteria, safety checks, and medical assessment process doctors use to decide who is eligible for Mounjaro® (tirzepatide) in Ireland.

Read

What weight loss injections are available in Ireland?

A clear breakdown of the three main medical treatments for weight management in Ireland in 2025 and 2026

Read

Who can't take Mounjaro? Understanding the contraindications

A comprehensive guide to the absolute contraindications and other cautions that determine who cannot safely take Mounjaro® (tirzepatide) in Ireland.

Read

Who Qualifies for Mounjaro in Ireland?

An overview of the clinical criteria, safety checks, and medical assessment process doctors use to decide who is eligible for Mounjaro® (tirzepatide) in Ireland.

Read

What weight loss injections are available in Ireland?

A clear breakdown of the three main medical treatments for weight management in Ireland in 2025 and 2026

Read

Who can't take Mounjaro? Understanding the contraindications

A comprehensive guide to the absolute contraindications and other cautions that determine who cannot safely take Mounjaro® (tirzepatide) in Ireland.

Read